BIXT BIOXYTRAN, INC
Pharmaceutical Preparations · OTC · SEC CIK 1445815 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-57.2%
TTM EPS YoY-50.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-1,453.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets1,582.1%
Debt / equity—
Current ratio0.03x
Interest coverage-25.47x
Cash quality & payout
Operating cash flow / net income0.25x
Accruals ratio-1,092.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $255,479 | $225,479 | $2,000 | $0 | $102,500 | $349,500 | $34,337 | $51,000 |
| SG&A expense | $189,121 | $213,974 | $235,799 | $159,131 | $94,529 | $143,770 | $399,452 | $158,071 |
| Operating income | -$654,600 | -$1.93M | -$607,285 | -$496,005 | -$224,077 | -$515,142 | -$483,688 | -$346,204 |
| Interest expense | $36,126 | $35,729 | $36,523 | $36,522 | $30,112 | $31,157 | $20,290 | $17,845 |
| Pretax income | -$619,929 | -$2.07M | -$522,155 | -$282,726 | $35,439 | -$1.35M | -$512,268 | -$392,374 |
| Net income | -$619,929 | -$2.07M | -$522,155 | -$282,726 | $35,439 | -$1.35M | -$512,268 | -$392,374 |
| EPS (basic) | -0.01 | -0.02 | — | 0.00 | 0.00 | -0.02 | — | 0.00 |
| EPS (diluted) | -0.01 | -0.02 | — | 0.00 | 0.00 | -0.02 | — | 0.00 |
| Weighted avg. shares (diluted) | 114.36M | 112.28M | — | 88.99M | 88.84M | 88.84M | — | 126.39M |
| Banking | ||||||||
| Deposits | — | $188,464 | $111,547 | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $177,384 | $463,047 | $509,914 | $14,499 | $3,144 | $4,348 | $5,154 | $34,672 |
| Current assets | $177,384 | $463,047 | $513,465 | $14,499 | $3,144 | $4,348 | $5,154 | $34,672 |
| Intangibles | $156,009 | $152,206 | $145,087 | $141,795 | $144,357 | $131,704 | $133,540 | $124,336 |
| Total assets | $333,393 | $615,253 | $658,552 | $156,294 | $147,501 | $136,052 | $138,694 | $159,008 |
| Current liabilities | $5.27M | $5.01M | $3.25M | $3.06M | $2.78M | $2.84M | $1.93M | $1.24M |
| Short-term debt | — | — | — | — | $48,070 | $48,000 | $48,000 | — |
| Total liabilities | $5.27M | $5.01M | $3.25M | $3.06M | $2.78M | $2.84M | $1.93M | $1.24M |
| Shareholders' equity | -$4.94M | -$4.39M | -$2.59M | -$2.90M | -$2.64M | -$2.71M | -$1.79M | -$1.08M |
| Shares outstanding | 114.70M | 113.36M | 108.15M | 88.99M | 88.99M | 88.88M | 86.78M | 82.24M |
| Cash flow statement | ||||||||
| Operating cash flow | -$349,773 | -$238,610 | -$236,971 | -$41,474 | -$80,687 | -$167,323 | -$127,937 | -$73,547 |
| Investing cash flow | -$9,383 | -$9,227 | -$6,240 | -$1,674 | -$15,162 | -$15 | -$12,071 | -$10,821 |
| Financing cash flow | $73,493 | $200,970 | $738,626 | $54,503 | $94,645 | $166,532 | $110,490 | $105,518 |
| Stock-based compensation | $7,815 | $1.29M | $84,574 | $43,741 | $40,461 | $26,998 | $446,508 | $8,416 |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.